We are updating our Privacy Policy and Terms and Conditions to help you clearly understand how your personal information is collected, stored and managed. Learn More
Menu Back toPrecision-Medicine-Gene-Editing-and-Gene-Therapy-Current-Status-and-Regulatory-Challenges-of-Integrating-Genetic-Medicine-into-Clinical-Care

DIA 2018 Global Annual Meeting

The DIA 2018 Global Annual Meeting brings together thousands of innovators from around the globe.

Precision Medicine, Gene Editing, and Gene Therapy: Current Status and Regulatory Challenges of Integrating Genetic Medicine into Clinical Care

    Session Chair(s)
      Tshaka  Cunningham, PhD

      Tshaka Cunningham, PhD

      • Associate Director, Scientific Collaboration
      • DIA, United States
    This DIAmond forum on precision medicine/gene therapy/gene editing will discuss the scientific, regulatory, and ethical/access issues surrounding these emerging technologies as they progress through the development process and become more integrated into clinical practice. Precision medicine is an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person. Gene editing and gene therapy are cutting edge molecular technologies that give scientists the ability to change an organism's DNA by allowing genetic material to be added, removed, or altered at particular locations in the genome, influencing desired gene expression. Collectively, these rapidly emerging disruptive technologies are poised to dramatically change the practice of medicine and transform patient care and disease monitoring and prevention in the future. There will be a diverse group of speakers in this session representing the various stakeholders in these areas represented including scientists, government regulators, pharmaceutical company and HMO executives, as well as patient advocates and experts on value and access.

    A particular focus of this forum will be a discussion of the anticipated changes in the global regulatory landscape for gene-based therapeutics and diagnostics as the technology in the space continues to evolve at a rapid pace.
    Learning Objective : Describe the development of next generation sequencing technology and it’s enabling of precision medicine; Discuss the development of CRISPR-based gene editing technology and its therapeutic application for genetic diseases such as Sickle Cell Disease; Identify prominent issues regarding regulation and pricing/reimbursement of gene-based therapeutics for disease and diagnostics for precision medicine.
      George  Church, PhD

      From Next Generation Sequencing to Gene Editing and Beyond: The Future of Gene-Based Medicine

      George Church, PhD

      • Robert Winthrop Professor of Genetics
      • Harvard University, United States
      Michael A. Friend

      Patient Perspective on Gene Editing and Gene Therapy: Can We Move Faster for a Cure for Sickle Cell Disease

      Michael A. Friend

      • Founder
      • Minority Coalition For Precision Medicine and Health Ministries Network, United States
      Peter W. Marks, MD, PhD


      Peter W. Marks, MD, PhD

      • Director, Center for Biologics Evaluation and Research
      • FDA, United States
      Samarth  Kulkarni, PhD


      Samarth Kulkarni, PhD

      • Chief Executive Officer
      • CRISPR Therapeutics, United States
      Christopher  O'Donnell, MD


      Christopher O'Donnell, MD

      • Chief Scientist, Million Veteran Program
      • US Department of Veteran Affairs, United States